Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19

Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19

29 Aug 2022

In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.

29 Aug 2022
Gout, hyperuricaemia meds less common among diabetics on SGLT2is

Gout, hyperuricaemia meds less common among diabetics on SGLT2is

28 Aug 2022

Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.

28 Aug 2022
Dulaglutide safely controls glucose in T2D with CKD

Dulaglutide safely controls glucose in T2D with CKD

28 Aug 2022

In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.

28 Aug 2022